News
News from us and our partners
News
News
Capital
News
Biovelocita
News
Crossover
News
Capital
News
In Memory of Denis Lucquin
Sofinnova Partners closes €650M ($750M) Capital XI, greatly exceeding initial target to back early-stage healthcare deals
Sofinnova Partners exceeds target with €165M biotech acceleration fund, Europe’s largest, with strong Pharma support
CEO spotlight: Thierry Abribat's third straight win
Johnson & Johnson to acquire Shockwave Medical
CEO spotlight: CinCor's Marc de Garidel
Tags
Topics
0 results
- News
In Memory of Denis Lucquin
- News
Biotalys achieves first milestone in bioinsecticide partnership with Syngenta
- News
Signadori Bio appoints Dr. Selwyn Ho, MB BS as Chief Executive Officer to lead company into next stage of growth
- News
Bioptimus Announces STELA: The World’s Largest Clinically Linked Spatial Biology Atlas, alongside key partners 10x Genomics and Broad Clinical Labs
- News
Abivax announces full year 2025 financial results and provides business updates
- News
Sensorion reports six-month update from the Audiogene Phase 1/2 Trial of SENS-501 and advances GJB2-GT (SENS-601) toward first-in-human clinical development
- News
Elevara Medicines doses first patient in Phase 2b START-SYNERGY trial of ELV001 in rheumatoid arthritis patients with incomplete response to TNFi
- News
May Health raises $11.7M to advance its novel technology to treat PCOS-related infertility
- News
Adapt or go extinct: Novameat unveils the ingredient that will save the global meat crisis
- News
MANE and Arzeda team up to offer next-gen sugar reduction solutions to the food and beverage industry
- News
Boehringer Ingelheim licenses novel oral therapeutics program for immune diseases from Sitryx Therapeutics
- News
Verley secures $38 million Series A to commercialize high-performance whey protein ingredients through precision fermentation
- News
GenSight Biologics Bolsters Regulatory Leadership in US and Europe with Two Senior Appointments
- News
Sensorion announces leadership changes
- News
Artios strengthens leadership team to accelerate late-stage development of potential first-in-class oncology pipeline